Hudson Holds Reins As Sanofi Makes Strides To Become R&D Powerhouse

06 Sep 2024

“For 20 or 30 years, we were not seen as a scientific leader,” the French major’s CEO tells Scrip. Now, things have started to change with several positive readouts coming out of its immunology portfolio.

Olympic horse — The iron horse from the opening ceremony of the Olympics will be on display at Sanofi's headquarters in Paris from October • Source: Alex Broadway via Getty Images (courtesy of Sanofi)

Paul Hudson, who has just celebrated his five year anniversary as CEO of Sanofi, feels that the firm is well on the way to being regarded as an elite R&D company, an area where it has lagged behind the industry’s research-based heavyweights.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Menarini’s APAC CEO On Harnessing Digital Channels, RWE And BD Engine

21 Apr 2025

• By Anju Ghangurde

In the final part of an interview with Scrip, Menarini’s Asia-Pacific CEO talks about the group’s digital capabilities, including their impact on a shortage issue in Australia, and leveraging RWE to inform healthcare practices across the region. The Italian company is also revving up its business development and alliance engine.

Executives On The Move: Six CMOs, Five CEOs And Two CSOs Among This Week’s Changes

17 Apr 2025

Recent moves in the industry include C-suite changes at Merck KGaA, Newleos Therapeutics and Artiva Biotherapeutics, plus Valo Therapeutics acquires chief executive officer from Johnson & Johnson.

The Silver Lining Of The US Pharma Security Investigation

15 Apr 2025

• By Jessica Merrill

An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Scrip about the latest developments.

Executives On The Move: Nine CEOs, Six CMOs And Three CFOs Among This Week’s Changes

11 Apr 2025

Recent moves in the industry include changes at the top at Novo Nordisk and Takeda, plus Nxera Pharma nabs chief commercial officer from AstraZeneca.

Samsung Bioepis Reevaluating Approach To Biosimilars

04 Apr 2025

• By Jessica Merrill

The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.